Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14589125 | 0.85 | KDM4E (0.51) | KDM4EAPAF1GAAMAPTHTT | |
| SCHEMBL3049322 | 0.84 | KDM4E (0.53) | KDM4EAPAF1GAAMAPTHTT | |
| SCHEMBL841946 | 0.82 | KDM4E (0.49) | KDM4EAPAF1GAAMAPTALDH1A1 | |
| SCHEMBL6820020 | 0.81 | NPC1 (0.44) | KDM4EAPAF1NPC1MAPTHTT | |
| SCHEMBL17917631 | 0.81 | ALDH1A1 (0.48) | KDM4EAPAF1NPC1GAAMAPT | |
| SCHEMBL1359424 | 0.79 | SMN1; SMN2 (0.49) | KDM4EAPAF1NPC1GAAMAPT | |
| SCHEMBL21753597 | 0.78 | KDM4E (0.45) | KDM4ENPC1GAAMAPTALDH1A1 | |
| SCHEMBL20874552 | 0.78 | GAA (0.51) | KDM4EAPAF1NPC1GAAMAPT | |
| SCHEMBL21753564 | 0.78 | NPC1 (0.44) | KDM4EAPAF1NPC1GAAMAPT | |
| SCHEMBL26924428 | 0.78 | NPC1 (0.44) | KDM4EAPAF1NPC1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058475-B2 | Substituted cyclohexylmethyl compounds | GRUENENTHAL GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| EP-1989174-B1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-08-03 | — | — | EP | claimed |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | GRUENENTHAL GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| CN-101384544-A | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | CN | claimed |
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4516301-A2 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4166539-B1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | PFIZER (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240287093-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-114681443-B | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2024-05-10 | — | — | CN | disclosed |
| EP-3842437-B1 | HIGH ACTIVITY STING PROTEIN AGONIST | ADLAI NORTYE BIOPHARMA CO LTD (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-116789648-A | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2023-09-22 | — | — | CN | disclosed |
| CN-1191063-C | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1478364-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040063765-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003039549-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| CN-1295471-A | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2001-05-16 | — | — | CN | disclosed |
| EP-1063982-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | Genentech, Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999049856-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287093-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | STING1, IRF3, MAVS | KDM4E 3778/4885APAF1 288/4885NPC1 541/4885 |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | KDM4E 1904/4885APAF1 572/4885NPC1 876/4885 |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | KDM4E 940/4885APAF1 4586/4885NPC1 112/4885 |
| US-20040063765-A1 | Modulation of pathogenicity | NR1H4, NR4A1, MSR1 | KDM4E 3783/4885APAF1 3685/4885NPC1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.